骨髓纤维化临床试验招募信息（全球在招）

这里汇总了全球正在招募患者的 骨髓纤维化（国际通用名 myelofibrosis）新药临床试验，包含试验分期、招募状态、开展国家和研究团队联系方式，全部以中文呈现。数据实时来自全球最大的临床试验注册库 ClinicalTrials.gov。

正在招募的骨髓纤维化新药试验

• Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

  I 期 / II 期招募中美国NCT07128381

• Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

  I 期 / II 期招募中美国NCT07281781

• Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm

  不适用招募中BelgiumNCT07590986

• Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

  I 期招募中美国NCT05025488

• Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

  不适用招募中美国德国意大利西班牙NCT06941025

• Two Step Haplo With Radiation Conditioning

  II 期招募中美国NCT05031897

• A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

  I 期招募中美国NCT07250646

• A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

  II 期招募中澳大利亚Brazil法国意大利NCT05037760

• Haplo-HSCT for Myelofibrosis

  不适用招募中中国NCT06674382

• Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

  早期 I 期招募中美国NCT06398457

• Momelotinib During and After HCT in Myelofibrosis

  I 期招募中美国NCT07104799

• Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

  II 期招募中美国加拿大法国德国NCT06517875